Why are we considering palmitoylethanolamide (PEA) for COVID19?

Why are we considering palmitoylethanolamide (PEA) for COVID19? We have been interested in this molecule for years and have used in our allergy patients (it has well-documented mast cell stabilizing properties), in our pain patients and as influenza treatment and prophylaxis. In this most recent COVID19 pandemic, I think PEA is worth considering, although we…

Clinician Position for SHC

Research and News February 2020

FDA Approves First Standardized Powder for Allergy Desensitization
Non-Stick Chemicals Found in Drinking Water Across US
Smoke-Damaged Cells Can Be Replaced – It’s Never Too Late To Quit
APOE4 Gene Carriers at Greater Risk for Memory Deficits from Soccer Headings
Antibodies Found in Rheumatoid Arthritis Linked with Chronic Obstructive Pulmonary Disorder (COPD)
Fish Oil May Improve Testicular Function